| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
This major strategic analysis provides a detailed insight into the current and
future market for targeted drug delivery technology.
Providing...
Critical analyses and competitive ratings for major specialist developers
Unique sales forecasts to 2015 for key current and new products utilising
targeted drug delivery technologies A comprehensive examination of this major
drug delivery sector
Whilst many approved and developmental drugs are well-tolerated, numerous
drugs need advanced delivery technologies to improve pharmacokinetics,
decrease toxicity, increase tolerability and ultimately enhance the
therapeutic index. Peripheral toxicity related to the systemic administration
of compounds can be dose limiting. However, the application of drug carrier
platforms (dendrimers, liposomes, polymers, micelles) can significantly
improve bio-distribution, whilst the addition of a targeted ligand
(antibodies, peptides, proteins, vitamins) can enhance the selective uptake of
drugs to target tissues or cells, thereby minimizing non-specific binding to
non-target tissue.
It is estimated that the advanced drug delivery market was worth around US$6.5
billion in 2006 with around 50% derived from targeted carrier systems and the
remainder derived from implants and intrauterine devices. Advances in polymer
technologies have enabled delivery specialists to design carriers for targeted
delivery either through direct drug conjugates or through polymer
formulations. However, one vehicle may not meet all delivery needs and
progress in liposome formulations has also met with considerable success.
The role of Mabs
Some developers have chosen to harness the natural ability of monoclonal
antibodies to target cells and where they may not make the grade as an
immunotherapeutic, they may become useful carriers for drugs and the delivery
of diagnostics and radiation. In addition, an array of antibody fragments and
other gene targeting agents (aptamers, oligonucleotides) are also under
investigation as targeting ligands for delivery.
This report identifies 25 companies which have active research and clinical
programmes evaluating targeted delivery carriers. By 2015 we anticipate 15 of
these companies may have new or improved formulations of approved products on
the market that will help to address the high unmet clinical need for
"targeted" therapies. It is anticipated that nearly 30 new products will enter
the market to generate an additional US$2 billion in advanced drug delivery
sales. These products cover a number of key therapy areas including, cancer,
cardiovascular and infectious disease.
Combination products are the future
Over time the line between each delivery system will become blurred as
combination delivery systems evolve to meet the specific needs for each
therapy class. As advances in nanotechnologies help to miniaturize delivery
platforms, developments in targeting vehicles will grow to ensure the specific
and selective intracellular and intranuclear delivery - providing the right
drug at the right time to the right cell.
TABLE OF CONTENTS
Executive Summary
- Competitor Ratio Analysis Summary
Introduction
Overview of delivery technologies for systemic targeted delivery: past, prese nt & future
- Systemic targeted delivery: motivators & resistors
Systemic targeted DELIVERY TECHNOLOGIES
- Types of systemic targeted delivery platform in development in the pharma
industry
- Targeting ligands
- Figure 1: Antibody-directed enzyme prodrug targeted delivery
- Figure 2: Peptide-induced release for targeted delivery
- Figure 3: Nucleomic mediated targeted intranuclear delivery
- Figure 4: Vitamin mediated targeted intracellular delivery - Cobalamin
- Non-biological targeting platforms
- Figure 5: Photosensitive targeted delivery
- Current therapeutic applications for systemic targeted delivery
- Leading systemic targeted products in development
- Table 1: Approved systemic and targeted drugs
- Future commercial applications & opportunities
STRATEGIES OF DRUG DELIVERY COMPANIES
- Leading targeted drug delivery companies
- Table 2: Leading systemic targeted delivery specialists
- Partnerships & acquisitions
- Strategic alliances
- Strategic acquisitions
- Table 3: Recent market activity in targeted delivery companies
- Intellectual Property
- Table 4: Targeted drug delivery patents
THE TARGETED Delivery MARKET
- Now 2007
- Table 5: Approved targeted delivery product sales
- Future 2015
- Table 6: Global controlled release product sales
- Table 7: Novel targeted delivery product sales
COMPETITOR ANALYSIS
- Movers & Shakers: Cutting edge or losing their grip
- Table 8: Movers & shakers in targeted drug delivery systems
COMPANY PROFILES
- Access Pharmaceuticals
- Figure 6: Schematic of targeted nanoparticle
- Table 9: Targeted delivery of cancer subtypes via folate polymer,
Vitamin B12 polymer and biotin polymers
- Table 10: Access Pharmaceuticals' product pipeline
- Table 11: Access Pharmaceuticals' targeted delivery sales forecasts
- ALZA
- Table 12: ALZA's product pipeline
- Table 13: ALZA's targeted drug delivery sales
- Avidimer Therapeutics
- Table 14: Avidimer's product pipeline
- Table 15: Avidimer's targeted drug delivery sales
- Calando Pharmaceuticals
- Figure 7: Schematic of cyclodextrin polymeric nanoparticles
- Table 16: Calando's product pipeline
- Table 17: Calando's targeted delivery sales forecasts
- Cell Therapeutics
- Figure 8: CTI's polyglutamate polymer technology
- Table 18: CTI's product pipeline
- Copernicus Therapeutics
- Table 20: Copernicus' product pipeline
- Table 21: Copernicus' targeted delivery sales forecasts
- Diatos SA
- Table 22: Diatos' product pipeline
- Table 23: Diatos' targeted drug delivery sales
- Enzon Pharmaceuticals, Inc.
- Table 24: Enzon's product pipeline
- Table 25: Enzon's targeted product sales
- Endocyte Inc.
- Table 26: Endocyte's product pipeline
- Table 27: Endocyte's targeted drug delivery sales
- Eurand
- Table 28: Eurand's product pipeline
- ImmunoGen
- Table 29: ImmunoGen's product pipeline
- Table 30: ImmunoGen's targeted delivery sales
- ImaRx Therapeutics
- Table 31: ImaRx' product pipeline
- Table 32: ImaRx' targeted product sales
- Insert Therapeutics
- Figure 9: Schematic of Cyclosert's nanoparticle mediated drug delivery
to solid tumours
- Table 33: Insert Therapeutics' product pipeline
- Table 34: Insert Therapeutics' targeted product sales
- Mirus Bio Corporation
- Figure 10: PolyConjugates - siRNA delivery system
- Table 35: Mirus' product pipeline
- NanoBioMagnetics, Inc
- Table 36: NanoBioMagnetics' product pipeline
- Nanobiotix
- Table 37: Nanobiotix' product pipeline
- NanoCarrier
- Figure 11: NanoCoat technology
- Table 38: NanoCarrier's product pipeline
- Table 39: NanoCarrier's targeted drug delivery sales
- NeoPharm
- Table 40: NeoPharm's product pipeline
- Table 41: NeoPharm's drug delivery sales
- Novosom AG
- Figure 12: Schematic of SMARTICLES mechanism of targeted delivery
- Table 42: Novosom's product pipeline
- PCI Biotech AS
- Figure 13: Schematic of principle of PCI technology
- Table 43: PCI's product pipeline
- Point BioMedical Corporation
- Figure 14: Schematic of Point's biSphere
- Table 44: Point's product pipeline
- Quest PharmaTech
- Table 45: Quest PharmaTech's product pipeline
- Seattle Genetics
- Figure 15: Schematic of ADC's
- Table 46: Seattle Genetic's product pipeline
- Table 47: Seattle Genetic's delivery sales
- Starpharma
- Table 48: Starpharma's product pipeline
- Supratek Pharma Inc.
- Table 49: Supratek's product pipeline
- Tekmira Pharmaceuticals Corporation
- Table 50: Tekmira's product pipeline
- Table 51: Tekmira's targeted delivery sales forecasts
APENDIX 1
- Table 52: Global targeted approved drugs sales 2006A-20015E
APENDIX 2
- Table 53: Global targeted developmental drugs sales 2006A-20015E
APENDIX 3
- Competitor Ratio Analysis Criteria
- Table 54: Key targeted delivery companies by 2015
BIBLIOGRAPHY
GLOSSARY
ACRONYMS
|
